In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Pharmaceuticals Inc.

www.alnylam.com

Latest From Alnylam Pharmaceuticals Inc.

Pfizer Wins Tafamidis Approval; Now It Will Need To Build The Market

Tafamidis was approved by FDA in two formulations that will be marketed as Vyndaqel and Vyndamax for the treatment of transthyretin amyloid cardiomyopathy.

Approvals Launches

Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.

Deals Business Strategies

Amyloidosis Drug PROs Supported Clinical Meaningfulness Of Objective Measures

In pivotal trials for Alnylam’s Onpattro and Ionis’ Tegsedi, statistically persuasive results on a patient-reported, quality-of-life measure were needed to show the drugs had a meaningful benefit on how hATTR patients with polyneuropathy feel and function, US FDA said.

Drug Review Profile Approvals

Onpattro, Tegsedi Cardiac Imaging And Serum Biomarker Data Failed To Impress US FDA

Pivotal studies of the first two drugs approved for treating hereditary transthyretin-mediated amyloidosis did not provide cardiac efficacy data on how patients feel, function or survive, reviewers said; the agency approved Alnylam’s patisiran and Ionis’ inotersen for patients with the polyneuropathy form of the disease but not the cardiomyopathy form.

Drug Review Profile Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Alnylam Holding Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • John M Maraganore, PhD, CEO
    Manmeet S Soni, CFO
    Pushkal Garg, MD, CMO
    Barry Greene, Pres.
    Yvonne Greenstreet, COO
    Saraswathy V Nochur, PhD, SVP, Chief Regulatory Officer
    Akshay Vaishnaw, MD, PhD, Pres, R&D
  • Contact Info
  • Alnylam Pharmaceuticals Inc.
    Phone: (617) 551-8200
    300 Third St., 3rd. Fl.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register